Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced positive preliminary results from a Phase III clinical trial of its complement inhibitor Fabhalta (iptacopan) for the treatment of IgA nephropathy (IgAN). The trial data showed that after a nine-month treatment period, the Factor B inhibitor Fabhalta reduced proteinuria by 38.3% when compared to a placebo. The drug also exhibited a favorable safety profile throughout the study.
Novartis has proactively submitted these interim findings to health authorities in the United States as part of an accelerated approval application, aiming to expedite the review process before the study’s scheduled completion in 2025.
As stated in the company’s press release, Fabhalta is the first-ever candidate drug for IgAN that specifically targets the alternative complement pathway, offering a novel therapeutic approach to this condition.- Flcube.com
